首页 / 院系成果 / 成果详情页

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years 期刊论文

编号：

5e7cc102-70c4-439d-9cde-6d415a75d21d
作者：

Zhang, Chi#*^[1,2]Zhang, Fan*^[3]Liang, Guanzhao^[4];Zeng, Xianshang^[5];Yu, Weiguang^[5];Jiang, Zhidao^[6];Ma, Jie(马洁)^[7]Zhao, Mingdong(赵明东)*^[8]Xiong, Min^[8];Gui, Keke^[8];Yuan, Fenglai*^[9,10]Ji, Weiping^[11,12];
语种：

English
期刊：

BMC MUSCULOSKELETAL DISORDERS ISSN：1471-2474 2018 年 19 卷 ; NOV 30
收录：
关键词：

Denosumab Zoledronic acid Breast cancer Symptomatic skeletal event Outcome analyses
摘要：

BackgroundThe purpose of this study was to evaluate the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events (SSEs) as the primary endpoint in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer.MethodsAsian postmenopausal women with oestrogen-receptor-positive advanced breast cancer receiving subcutaneous denosumab 120mg Q4W, or intravenous ZA 4mg Q4W until the primary analysis cut-off date were retrospectively analysed in the Hong Kong Practice-Based Cancer Research Center(HKCRC) from March 2011 to March 2013. The time to first on-study SSE that was assessed either clinically or through routine radiographic scans was the primary endpoint.Results242 patients received denosumab or ZA treatment (n=120, mean age of 64.9years (SD 3.01) and n=122, 65.4years (3.44), respectively). The median times to first on-study SSE were 14.7months (12.9-45.6) and 11.7months (9.9-45.6) for denosumab and ZA, respectively (hazard ratio, HR 0.44, 95% CI 0.71-2.95; p=00002). Compared with the ZA group, denosumab-treated patients had a significantly delayed time to first SSE (HR 0.65 [95% CI 0.29-1.45], p<0.0001). An increased incidence of SSE was found in the 16-month follow-up with rates of 2.1 and 10.7% for denosumab and ZA, respectively (P=0.033). The difference persisted with time with rates of 8.3 and 17.2% at the final follow-up, respectively (P<0.05).ConclusionIn postmenopausal women aged 60years with oestrogen-receptor-positive advanced breast cancer, denosumab significantly reduced the risk of developing SSEs compared with ZA. The findings of this pilot trial justify a larger study to determine whether the result is more generally applicable to a broader population.
推荐引用方式
GB/T 7714：

Zhang Chi,Zhang Fan,Liang Guanzhao, et al. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years [J].BMC MUSCULOSKELETAL DISORDERS,2018,19.
APA：

Zhang Chi,Zhang Fan,Liang Guanzhao,Zeng Xianshang,&Ji Weiping.(2018).Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years .BMC MUSCULOSKELETAL DISORDERS,19.
MLA：

Zhang Chi, et al. "Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years" .BMC MUSCULOSKELETAL DISORDERS 19(2018).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：62  下载次数：0

分享到：

浏览次数：62

下载次数：0

打印次数：0